(Q36909396)

17 August 2017

1 reference

title

Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge). (English)

1 reference

17 August 2017

1 reference

1 reference

2

Eric J Small

1 reference

17 August 2017

Andrea L Harzstark

1

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 August 2007

1 reference

Expert Opinion on Biological Therapy

17 August 2017

published in

1 reference

17 August 2017

volume

7

1 reference

17 August 2017

issue

8

1 reference

17 August 2017

page(s)

1275-1280

1 reference

17 August 2017

cites work

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1275

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1275

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1275

Gene expression and prostate specificity of human prostatic acid phosphatase (PAP): evaluation by RNA blot analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1275

Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1275

A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1275

Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1275

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1275

Natural history of progression after PSA elevation following radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1275

The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1275

Augmentation of T Cell Levels and Responses Induced by Androgen Deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.8.1275

10.1517/14712598.7.8.1275

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference